Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charlotte Hobbs

Pediatrics Minneapolis, MN Medical Doctor

NPI 1134219637 CMS profile 850834

2925 Chicago Ave, Minneapolis, MN 55407

Open in the dashboard

General payments

$29,592

46 records reported · program years 2019–2025

Research payments

$11,005

Paid to them · 27 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,083 paid to institutions, not to them · program year 2024

Through program year 2025, Charlotte Hobbs of Minneapolis, MN is reported in the CMS Open Payments database as having received $29,592 across 46 general payments and $11,005 in research payments paid to them. Separately, studies naming them as principal investigator received $1,083 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,582 12
2025 Research $2,908 6
2024 General $2,214 3
2024 Research $2,299 3
2023 General $8,335 5
2023 Research $1,082 5
2022 General $1,262 8
2022 Research $4,657 11
2021 General $2,194 4
2020 General $1,479 4
2020 Research $34 1
2019 General $4,527 10
2019 Research $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charlotte Hobbs
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Charlotte Hobbs were reported at $9,582. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Charlotte Hobbs Pediatrics median Middle half National median
2019 $4,527 $86 $31–$183 $163
2020 $1,479 $49 $22–$110 $114
2021 $2,194 $68 $27–$158 $132
2022 $1,262 $77 $30–$173 $149
2023 $8,335 $88 $33–$190 $160
2024 $2,214 $94 $34–$206 $164
2025 $9,582 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $7,504 3 payments
  2. Zydus Pharmaceuticals (USA) Inc. $5,608 5 payments
  3. Amneal Pharmaceuticals LLC $5,092 4 payments
  4. Aurobindo Pharma USA, Inc. $2,567 2 payments
  5. Eli Lilly and Company $2,194 4 payments
  6. Akorn, Inc. $1,700 3 payments
  7. Hikma Pharmaceuticals USA $1,546 12 payments
  8. AbbVie, Inc. $1,050 1 payment
  9. Allergan Inc. $1,000 1 payment
  10. Mylan Inc. $708 1 payment
  11. Other $623 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $15,739 35 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,396 4 payments
  3. Honoraria $3,200 3 payments
  4. Travel and Lodging $2,849 2 payments
  5. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $2,408 2 payments
Products named General payments · program years 2019–2025
  1. MYCOPHENOLATE MOFETIL Internal Medicine $5,092 4 payments
  2. MYCOPHENOLATE $2,567 2 payments
  3. Mycophenolate Mofetil Immunosuppressant $1,700 3 payments
  4. Mycophenolate Mofetil Rheumatology $1,285 4 payments
  5. SAVELLA $1,000 1 payment
  6. Mycophenolate Mofetil Immunology $741 3 payments
  7. Non-Product Related $300 2 payments
  8. MYCOPHENOLATE MOFETIL Immunology $290 6 payments
  9. Antiretroviral Pregnancy Registry $261 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Mylan Inc. $6,025 7 payments
  2. Accord Healthcare, Inc. $3,072 6 payments
  3. CutisPharma, Inc. $1,400 1 payment
  4. Teva Pharmaceuticals USA, Inc. $384 9 payments
  5. Apotex Inc. $124 4 payments

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record